News
Mission drives innovation, and innovation improves quality of life
News
-
AACR 2025 | Preclinical Results of TGRX-3911 Unveiled, Potentially Addressing Clinical Resistance Challenges of Current BTK Inhibitors2025-04-30 Views:26
TargetRx presented preclinical data of its oral BTK degrader TGRX-3911 at the 2025 American As ...
-
AACR 2025 | Preclinical Data Disclosure of TGRX-3544: An Oral, Highly Mutant-selective KIT Degrader2025-04-30 Views:32
At the 2025 AACR Annual Meeting, TargetRx presented preclinical results for TGRX-3544 for the first time i ... -
AACR 2025 | TargetRx Reveals First Preclinical Data on Two Novel, Oral Potent Protein Degraders2025-03-28 Views:115
Two novel targeted protein degraders (TPD) developed by TargetRx - TGRX-3544, an orally active and highly mutation ... -
TargetRx Completes Series C Financing2025-01-22 Views:800
Shenzhen TargetRx, Inc announced today that it has successfully completed its Series C financing, raising $50 mil ... -
2024 ASH Poster | Preclinical Results of TGRX-678 on Its Potential Blood-Brain Barrier Penetration Ability2024-12-16 Views:125
At the 66th Annual Meeting of the American Society of Hematology (ASH) in 2024, Shenzhen Ta ... -
2024 ASH Poster | TargetRx Presents Preclinical Results of TGRX-3247, a Highly Potent, Broad-Spectrum Oral BCR::ABL1 Degrader2024-12-16 Views:154
TargetRx presented the preclinical research results of TGRX-3247 for the first time at the 6 ...
Tel: +86-0755-86934300
3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: 